key: cord-0902312-2axyombe
authors: Bassetti, Matteo; Magnasco, Laura; Vena, Antonio; Portunato, Federica; Giacobbe, Daniele Roberto
title: Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?
date: 2022-02-03
journal: Curr Opin Infect Dis
DOI: 10.1097/qco.0000000000000813
sha: 571f3d8985d3c8edc1c7260c6a4fc6b2428154e5
doc_id: 902312
cord_uid: 2axyombe

Some patients with coronavirus disease 2019 (COVID-19) may develop pulmonary bacterial coinfection or superinfection, that could unfavorably impact their prognosis. RECENT FINDINGS: The exact burden of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in peculiar populations such as patients with COVID-19 remains somewhat elusive, possibly because of wide heterogeneity in methods and endpoints across studies. SUMMARY: There was important heterogeneity in the retrieved literature on the epidemiology of MRSA lung infection in patients with COVID-19, both when considering all other bacteria as the denominator (relative prevalence ranging from 2% to 29%) and when considering only S. aureus as the denominator (relative prevalence ranging from 11% to 65%). Overall, MRSA is among the most frequent causative agents of pulmonary infection in patients with COVID-19. Improving our ability to rapidly reach etiological diagnosis of bacterial lung infection in COVID-19 patients remains fundamental if we are to improve the rates of appropriate antibiotic therapy in patients with COVID-19 and concomitant/superimposed MRSA infection, at the same time avoiding antibiotic overuse in line with antimicrobial stewardship principles.

Some patients with coronavirus disease 2019 (COVID-19) may develop pulmonary bacterial coinfection or superinfection, that could unfavorably impact their prognosis [1,2,3 & ]. Overall, the prevalence of bacterial pneumonia in hospitalized patients with COVID-19 has been reported to reach 7%, with the risk of community-acquired bacterial pneumonia (CABP) being lower than that of developing hospital-acquired bacterial pneumonia (HABP), especially ventilatorassociated bacterial pneumonia (VABP) [4] [5] [6] .

Although not the most frequent, Staphylococcus aureus is a well recognized cause of bacterial pneumonia in general [7] [8] [9] [10] . In particular, a non-negligible risk of developing S. aureus pulmonary infection has been reported in patients with severe influenza, with also a high crude mortality of >50% [11] . Another factor associated with increased mortality in patients with S. aureus pneumonia in previous studies was the presence of methicillin resistance [7, 9, [12] [13] [14] . Overall, methicillin-resistant S. aureus (MRSA) has been reported to cause up to 9% and 23% of CABP and HABP, respectively. However, the exact burden of MRSA lung infection in peculiar populations such as patients with COVID-19 remains somewhat elusive, possibly because of wide heterogeneity in methods and endpoints across studies (with many of them focused on other aspects and reporting only marginally on the epidemiology of causative agents of bacterial co-infection or superinfection), as well as in the approach to etiological diagnosis (e.g., different frequencies of collection of deep respiratory specimens for culture or molecular testing in COVID-19 patients with VABP) [1, 2, 4, [15] [16] [17] [18] [19] [20] [21] [22] .

In this narrative review, we discuss existing observational studies reporting either selectively or marginally on the epidemiology of S. aureus and MRSA pulmonary co-infection or superinfection in patients with COVID-19, in the attempt to provide a global overview of its prevalence in this population.

In September 2021, we performed a literature search through the PubMed online database, using various combinations of the keywords 'COVID-19', 'aureus', and 'MRSA'. Then, title and abstract screening were performed in order to check consistency with the selected topic, followed by full text review of selected papers and pertinent references. Eventually, observational studies reporting on the epidemiology of S. aureus and/or MRSA pneumonia in patients with COVID-19 were included in the present review and narratively discussed.

The characteristics of available studies reporting on the epidemiology of S. aureus and MRSA lung infection in patients with COVID-19 are summarized in Table 1 . As shown in the table, there is certainly heterogeneity in the study populations (hospitalized patients with COVID-19 vs. only critically ill patients with COVID- 19) , but the two most important factors hampering a clear delineation of the prevalence of MRSA pneumonia in COVID-19 patients are the different denominators exploited for assessing absolute/relative prevalence of lung infection (e.g., whole study population, patients who underwent microbiological investigation, patients with positive cultures, presence/lack of clear definition for lung infection) and the level of details of information (e.g., antimicrobial susceptibility of S. aureus isolates). Keeping in mind these crucial limitations, the results of available studies providing information on MRSA lung infection epidemiology are discussed in the following paragraphs. With regard to mortality of S. aureus and MRSA lung infections in patients with COVID-19 (also reported in the last column of Table 1 , whenever the information was available with sufficient detail), it should be acknowledged that we focused on studies from which we could extrapolate prevalence data, and thus this narrative review was not primarily aimed to delineate mortality of MRSA lung infection. A recent scoping review was conversely aimed to synthetize available evidence on clinical outcomes in patients with COVID-19 and S. aureus coinfection, reporting a crude mortality of 65% in 115 coinfected patients (mostly bacteremia, followed by pneumonia) from 28 studies, also including case reports [23] . Mortality was not stratified in detail for methicillin susceptibility [23] .

As anticipated in the previous paragraph, a general stratification can be made based on the study population: hospitalized patients with COVID-19; only critically ill patients with COVID-19. In addition, another important division in the retrieved literature, which we considered for the organization of the following paragraphs, was: studies reporting on the epidemiology of S. aureus lung infection (without providing information on S. aureus antimicrobial susceptibility); studies reporting information on the epidemiology of MRSA lung infection.

With regard to studies reporting on the epidemiology of S. aureus lung infection in general, Silva and . Several other organisms (e.g., Pseudomonas aeruginosa, Enterobacterales) were more frequently isolated than S. aureus, but it should be noted that this count also included infections other than pneumonia [26] . In a large retrospective, multicenter study in England, including 223 413 hospitalized patients with COVID-19, bacterial infections were diagnosed in 2279/223 413 cases (1%) [27] . Of 2279 bacterial infections, 209 were early S. aureus infections (defined as co-infections), and 301 late S. aureus infections during hospitalization (defined as secondary infections). Of the cumulative 510 patients with S. aureus infections, 262 had respiratory infections (51%). Overall, S. aureus was the most frequent causative agent of respiratory infections in this large cohort (with early and late infections being considered together for this calculation) [27] . In a prospective, single center study conducted in Peru, among 93 hospitalized patients with COVID-19, 11 patients had sputum culture yielding S. aureus (12%), which was the most frequently isolated pathogen from sputum [21] . In a crosssectional, multicenter study of 399 hospitalized patients with COVID-19 in Colombia, 18 of them had respiratory S. aureus infection (5%). In terms of frequency as causative agent of respiratory ]. In a retrospective, single center study conducted by Tang et al. [22] in 142 hospitalized patients with COVID-19 in China, 32/142 patients had positive sputum cultures (23%), of which 6/32 were positive for S. aureus (19%). Together with P. aeruginosa, S. aureus was the second most frequently isolated bacterial pathogen from sputum after K. pneumoniae [22] . In a retrospective, single center study by Yang et al., among 20 critically ill patients with COVID-19 for a total of 96 respiratory samples, bacteria were identified in 56/96 cases (58%) [29] . S. aureus was identified from 7% and 31% of specimens by conventional culture and by polymerase chain reaction (PCR), respectively [29] . In a retrospective, single center study of 107 critically ill patients with COVID-19, 35 had VABP (33%), and 8/35 episodes were caused by S. aureus (23%) [30] . In this latter study, P. aeruginosa and Klebsiella spp. were isolated from respiratory specimens slightly more often than S. aureus [30] .

With regard to studies providing information on the epidemiology of MRSA lung infection, in a retrospective study of hospitalized patients with COVID-19 who developed S. aureus bacteremia, Cusumano et al. [31] identified pneumonia as the source of bacteremia in 19% of cases (8/42) , mostly hospital-acquired (only two cases were CABP). Overall, 19/42 blood isolates were MRSA (45%), but no details were provided on how many were isolated from the eight patients who also had pneumonia [31] . In a multicenter, retrospective study conducted by Son et al. in South Korea, 47 patients had available culture results among 152 hospitalized patients with COVID-19 (31%) [32] . Of them, 3/47 had respiratory cultures positive for MRSA (6%) [32] . In a single center, cross-sectional study of 43 hospitalized patients in Iran with COVID-19 and positive bacterial cultures, 6/43 patients had cultures positive for MRSA (14%), with two being cultures of respiratory specimens [33] . In another single-center, retrospective study, conducted among 1495 hospitalized patients with COVID-19 in Wuhan, China, 102/1495 were reported to have secondary bacterial infection (7%), and 3/102 had positive MRSA cultures (2/3 were from respiratory specimens) [34] . In this study from Wuhan, Gram-negative bacteria were more frequently isolated than MRSA from respiratory specimens (43% and 31% for Acinetobacter baumannii and Klebsiella pneumoniae, respectively, vs. 2% for MRSA) [34] . In a retrospective, single center study conducted in the United States, among 4221 hospitalized patients with COVID-19 there were 472/4221 with available respiratory culture results (11%) [35] . The prevalence of MRSA in respiratory cultures ranged from a 0.6% on day 3, to 5.7% on day 28, cumulatively [35] . In a retrospective, single center, Spanish study involving 1195 hospitalized patients with COVID-19, bacteria were detected from cultures of respiratory specimens in 66/1195 patients (6%), with S. aureus being identified in 18/66 cases (and 8/18 were MRSA, 44%) [36] . S. aureus was the most frequently isolated pathogen from respiratory specimens, followed by P. aeruginosa (17/66) [36] . In a multicenter, retrospective study in 836 hospitalized patients with COVID-19 in the UK, S. aureus was the most frequent pathogen isolated from respiratory samples (sputum or bronchoalveolar lavage fluid [BALF]) collected within 5 days of admission (4/14, 29%), whereas S. aureus was less frequently isolated than P. aeruginosa and Enterobacterales from positive respiratory samples collected beyond 5 days of admission (2/19, 11%) [37] . In a retrospective, single center study in Italy, Fontana et al. [38] evaluated 152 respiratory samples from consecutive COVID-19 patients by multiplex polymerase chain reaction. Overall, 21/66 positive BALF samples yielded S. aureus (32%), of which 16/ 21 were mecA positive (76%), and 27/86 positive sputum samples yielded S. aureus (31%), of which 14/27 were mecA positive (52%). In this latter study by Fontana et al. [38] , S. aureus was the most frequently detected pathogen from respiratory samples. In a single center, retrospective study in 314 hospitalized patients with COVID-19, a diagnosis of probable VABP due to methicillin-susceptible S. aureus (MSSA) and MRSA was posed in two and one patients, respectively [39] . Baskaran et al. [40] conducted a retrospective study among 254 critically ill patients with COVID-19, of whom 4/254 had S. aureus colonization/infection at ICU admission or within 48 h after admission, with 1/4 being MRSA. In the same study, the relative prevalence of late S. aureus co-colonization/co-infection was also collected, being between 5% and 10% both 3-7 days and >7 days after ICU admission. Overall, S. aureus was the most frequently isolated pathogen within 48 h of ICU admission, whereas Gram-negative bacteria predominated subsequently [40] . Grasselli et al. [2] conducted a multicenter, retrospective study in 759 critically ill patients with COVID-19, calculating an incidence rate of VABP of 26 episodes per 1000 ICU days, for a total of 389 VABP episodes. Overall, 110/389 VABP were caused by S. aureus, with 61/110 being caused by MRSA (55%). Overall, S. aureus was the most frequently isolated pathogen from patients with VABP, although most VABP episodes were caused by Gram-negative bacteria (64%). Giacobbe et al. [16] registered an incidence rate of 18 VABP events per 1000 ventilator days among 586 critically ill patients with COVID-19 in a multicenter study in Italy. Overall, 171/586 of patients developed VABP (29%), and 77/171 patients with VABP had positive BALF cultures. S. aureus VABP and MRSA VABP were diagnosed in 18/77 cases (23%) and 8/77 cases (10%), respectively. S. aureus was the second most frequently isolated pathogen after P. aeruginosa [16] . In a retrospective, single center study of 101 critically ill patients with COVID-19, of whom 20/101 had positive respiratory cultures (20%), Elabbadi et al. [41] reported a relative prevalence of S. aureus of causative agent of pulmonary infection of 55% (11/20), with 2/11 isolates being MRSA (18%). S. aureus was the most frequent pathogen isolated in this cohort [41] . In a prospective, single center study of 40 critically ill patients with COVID-19 and S. aureus VABP in Italy, MRSA was responsible for 65% of cases [15] . Sharifipour [43] . In this cohort, S. aureus was preceded by P. aeruginosa and K. pneumoniae in terms of relative frequency of detection [43] . Among 43 critically ill patients with COVID-19 who underwent bronchoscopy, a total of 96 BALF samples were collected [44] . Overall, there were 5/43 patients with first BALF drawn positive for S. aureus (12%) and 6/43 patients with subsequent BALF specimens positive for S. aureus (6/ 43, 14%). The mecA gene was detected in two cases. The only pathogen isolated more frequently than S. aureus was P. aeruginosa [44] . In a retrospective, single center study of 197 critically ill patients with COVID-19 in Egypt, 18/197 were diagnosed with VABP due to MRSA (9%), which overall was less frequent than VABP due to Gram-negative bacteria [45] . In a retrospective, single center study of 196 critically ill patients with COVID-19, 28 had BALF culture performed within 48 h from intubation, with MSSA and MRSA being isolated in 11/28 (39%) and 2/28 (7%) cases, respectively [46] . With regard to positive samples drawn beyond 48 h of intubation (n ¼ 120), 15 and 10 of them yielded MSSA and MRSA, respectively, with S. aureus being the most frequently isolated pathogen [46] . In a retrospective, multicenter study conducted in 188 critically ill patients with COVID-19 there were 141 VABP, with S. aureus accounting for 14% of episodes [47] . S. aureus was the most frequently isolated pathogen from respiratory specimens, and most of S. aureus isolates (24/28) were from late VABP. Overall, 3/28 S. aureus isolates were MRSA (11%) [47] . In a retrospective, single center study of 50 critically ill patients with COVID-19 requiring extracorporeal membrane oxygenation (ECMO), 43/50 developed at least one VABP episode (86%). [48] . S. aureus was isolated in three episodes (7%), of which one was caused by MRSA and two by MSSA. Enterobacterales and nonfermenting Gram-negative bacteria were isolated more frequently than S. aureus [48] . In a single center retrospective study conducted in 140 critically ill patients with COVID-19, development of VABP was registered in 21/140 patients (15%), and in five cases was caused by MRSA (24%) [49] . In this latter study, MRSA was the second most frequently isolated pathogen from respiratory specimens following P. aeruginosa [49] . Finally, in a multicenter, retrospective study, of 586 critically ill COVID-19 patients, 287 of them developed ventilator-associated lower respiratory tract infections (VABP or tracheobronchitis) [50 & ]. Overall, 27 episodes were caused by MSSA (10%) and 8 by MRSA (3%). Most ventilator-associated lower respiratory tract infections were caused by Gram-negative bacteria (84%) [50 Some brief considerations on the relative risk of methicillin-resistant Staphylococcus aureus vs. methicillin-susceptible Staphylococcus aureus lung infection in coronavirus disease 2019 patients While a specific, formal statistical analysis of any possible independent association of potential predisposing factors with the development of MRSA lung infection in COVID-19 is not available, it is of note that the available relative frequency of MRSA vs. MSSA as causative agent of lung infection in COVID-19 suggest a relative prevalence of MRSA >30% in COVID-19 patients with VABP, whereas a study reported a relative frequency of MRSA <30% as a causative agent of CABP [2,16,39,40,42,47, 48,50 & ]. While this may suggest late infection during hospitalization as a reasonable potential risk factor for MRSA, such crude relative prevalences should still be interpreted with caution pending further investigation, especially considering the limited information on the relative prevalence of MRSA as causative agent of CABP in this patient population. Furthermore, many studies reported the relative prevalence of MRSA lung infection in COVID-19 patients at ICU admission, which, without providing additional details, does not allow to clearly understand whether the patients had CABP, HABP, or ventilated HABP.

Another factor certainly deserving further investigation as a potential risk factor for MRSA infection in COVID-19 patients is previous antibiotic therapy. Of note, this applies both to CABP (empirical antibiotic therapy at home) and to HABP/VABP (previous therapy either at home or in the hospital). Unfortunately, most initial experiences registered a large, likely excessive, use of antibiotics in COVID-19 patients, a fact that significantly hampered any possible reliable assessment of the role of previous therapy in independently influencing the risk of MRSA infections [4] [5] [6] .

In the previous paragraphs, we narratively summarized the results of studies reporting on the epidemiology of S. aureus and MRSA lung infection in patients with COVID-19. Of note, our summary was qualitative and not quantitative, thereby not allowing to provide proper quantitative measures, but at the same time relaxing inclusion criteria and allowing a wider qualitative interpretation. Overall, keeping into account the wide heterogeneity in study designs, populations, and denominators, as well as the wide range of the relative prevalences of S. aureus lung infection registered in the different studies (2-36%), the following general trajectories seem to stem from the currently available literature on the epidemiology of S. aureus lung infection in COVID-19 patients: S. aureus is among the most frequently isolated bacteria from the respiratory tract of patients with COVID-19 during the first days of hospitalization; conversely, although S. aureus remains one of the most frequently isolated pathogen also in late secondary respiratory infections (that overall are far more frequent than early infections), Gram-negative bacteria frequently predominate in late scenarios. Nonetheless, S. aureus predominated as cause of HABP/VABP in some local scenarios. In this regard, the hypothesis-generating findings of De Pascale et al. [15] , who reported a lower species diversity and enrichment in S. aureus in the lung microbiota of critically ill COVID-19 patients with S. aureus VABP in comparison with non-COVID-19 critically ill patients with S. aureus VABP, is intriguing and deserves further investigation.

Regarding MRSA lung infection in patients with COVID-19, there was important heterogeneity in the retrieved literature on its epidemiology, both when considering all other bacteria as denominator (relative prevalence ranging from 2% to 29%) and when considering only S. aureus as denominator (relative prevalence ranging from 11% to 65%). All of this likely reflect the local microbiological epidemiology, although it should be noted that MRSA was not rare as causative agent of CABP in patients with COVID-19, therefore, in our opinion, it may be prudent to consider it in patients presenting with severe COVID-19 pneumonia and high suspicion of bacterial co-infection. Against this background, improving our ability to rapidly detect the causative agents of pneumonia and their crucial resistance determinants in COVID-19 patients (either through conventional or molecular methods) remains, in our opinion, fundamental if we are to improve our rates of appropriate empirical therapy in patients with COVID-19 and concomitant/ superimposed MRSA infection, at the same time avoiding antibiotic overuse in line with antimicrobial stewardship principles.

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Hospital-acquired infections in critically ill patients with COVID-19

Ventilator-associated pneumonia in patients with COVID-19: a systematic review and meta-analysis

A recent meta-analysis reporting pooled estimates of developing ventilator-associated pneumonia in critically ill patients with COVID-19

Clinical management of adult patients with COVID-19 outside intensive care units: guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)

Co-infections in people with COVID-19: a systematic review and meta-analysis

Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

Staphylococcus aureus pneumonia in the community

Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culturepositive pneumonia

Pneumonia caused by methicillin-resistant Staphylococcus aureus

Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study

Epidemiology of postinfluenza bacterial pneumonia due to Panton-Valentine leucocidin positive Staphylococcus aureus in intensive care units: a retrospective nationwide study

Staphylococcus aureus bacteremic pneumonia

Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms

Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes

Staphylococcus aureus ventilatorassociated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis

Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study

Use of ceftaroline in hospitalized patients with and without COVID-19: a descriptive cross-sectional study

Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel Plus Assay

Characterization of secondary bacterial infections and antibiotic use in mechanically ventilated patients with COVID-19 induced acute respiratory distress syndrome

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

Large multicenter study showing that the prevalence of bacterial coinfection in COVID-19 patients is low compared with the risk of subsequent secondary bacterial infections

Detection of viral and bacterial respiratory pathogens identified by molecular methods in COVID-19 hospitalized patients and its impact on mortality and unfavorable outcomes

Analysis of pathogens and risk factors of secondary pulmonary infection in patients with COVID-19

Clinical outcomes in patients coinfected with COVID-19 and Staphylococcus aureus: a scoping review

Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients

SARS-CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: secondary bacterial pneumonia and viral coinfections

Coinfections in patients hospitalized with COVID-19: a descriptive study from the United Arab Emirates

National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave

Bacterial superinfection in adults with COVID-19 hospitalized in two clinics in Medellin-Colombia

Bacterial and fungal co-infections among COVID-19 patients in intensive care unit

Secondary infections in mechanically ventilated patients with COVID-19: An overlooked matter?

Staphylococcus aureus bacteremia in patients infected with COVID-19: a case series

Risk factors for isolation of multidrug resistant organisms in coronavirus disease 2019 pneumonia: a multicenter study

Bacterial co-infections and antibiotic resistance in patients with COVID-19

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia

Bacterial coinfections in COVID-19 pneumonia in a tertiary care hospital: surfing the first wave

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Co-infections observed in SARS-CoV-2 positive patients using a rapid diagnostic test

Increased rates of secondary bacterial infections, including Enterococcus bacteremia, in patients hospitalized with coronavirus disease 2019 (COVID-19)

Co-infection in critically ill patients with COVID-19: an observational cohort study from England

Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia

Evaluation of bacterial coinfections of the respiratory tract in COVID-19 patients admitted to ICU

Respiratory bacterial co-infections in intensive care unit-hospitalized COVID-19 patients: conventional culture vs BioFire FilmArray pneumonia Plus panel

Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19

Bacterial and fungal ventilator associated pneumonia in critically ill COVID-19 patients during the second wave

Bacterial superinfection pneumonia in patients mechanically ventilated for COVID-19 pneumonia

Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an un-inundated French region

Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study

Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

A large multicenter study assessing the risk of ventilator-associated lower respiratory infections in patients with COVID-19 compared to other critically ill populations

International ERS/ESICM/ESCMID/ ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospitalacquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT)

Surveillance definitions for specific types of infections 2020

Clinical and microbiological features of asymptomatic SARS-CoV-2 infection and mild COVID-19 in seven crewmembers of a cruise ship

COVID-19 and co-infection in children: the Indian perspectives

High rate of multidrug-resistant organisms (MDROs) among COVID-19 patients presenting with bacteremia upon hospital admission

Management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the

Predictors of severity and co-infection resistance profile in COVID-19 patients: first report from upper Egypt

Bacterial co-infection in patients with SARS-CoV-2 in the Kingdom of Bahrain

Coinfections with other respiratory pathogens among patients with COVID-19

Ventilator-associated pneumonia in critically ill patients with COVID-19

ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units

Extensive microbiological respiratory tract specimen characterization in critically ill COVID-19 patients

High prevalence of antibiotic resistance among opportunistic pathogens isolated from patients with COVID-19 under mechanical ventilation: results of a single-center study

Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU

European Centre for Disease Prevention and Control. Surveillance of healthcare-associated infections in intensive care units: HAI Net ICU protocol, version 2.2. LU: Publications Office

Ventilator-associated bacterial pneumonia in coronavirus 2019 disease, a retrospective monocentric cohort study

Community-acquired and hospitalacquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease

Financial support and sponsorship None.

Outside the submitted work, MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea,